Taku Hatano - Concepedia

Author

Taku Hatano

Also Known As

Hatano Taku, Hidemoto Saiki, On behalf of the Yokukansan Parkinson’s Disease Study Group, T Hatano, T. Hatano, TAKU HATANO, Takashi Ogawa, Taku HATANO, Taku Hatano, taku Hatano

264

Publications

6.6K

Citations

H-Index

132

Concepts

All Affiliations

Juntendo University The University of Tokyo Dokkyo Medical University Saitama Medical Center Toho University Juntendo University Shizuoka Hospital

About

Taku Hatano is an author at Juntendo University specializing in medicine, neurology, and neuroscience.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	36	2.2K
2	Health Sciences	9	9	443
3	Engineering	4	4	279
4	Natural Sciences	2	2	230
5	Public Health	1	1	14

Taku Hatano

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
LRRK2 regulates synaptic vesicle endocytosis Narae Shin, Hyerhan Jeong, Jungsun Kwon, Experimental Cell Research Molecular NeuroscienceSignal TransductionSynaptic Vesicle EndocytosisSynaptic TransmissionEndocytic Pathway	2008	325
Propagative α-synuclein seeds as serum biomarkers for synucleinopathies Ayami Okuzumi, Taku Hatano, Gen Matsumoto, Nature Medicine	2023	286
Identification of novel biomarkers for Parkinson's disease by metabolomic technologies Taku Hatano, Shinji Saiki, Ayami Okuzumi, Journal of Neurology Neurosurgery & Psychiatry	2015	268
PINK1 is recruited to mitochondria with parkin and associates with LC3 in mitophagy Sumihiro Kawajiri, Shinji Saiki, Shigeto Sato, FEBS Letters	2010	243
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study Vera Bril, Artur Drużdż, Julian Großkreutz, The Lancet Neurology Clinical TrialsGeneralised Myasthenia GravisPharmacotherapyMedicineAnesthesiology	2023	227
Leucine-rich repeat kinase 2 associates with lipid rafts Taku Hatano, Shinichiro Kubo, Satoshi Imai, Human Molecular Genetics Neurodegenerative DiseasesSignal TransductionLipid RaftsNatural SciencesReceptor Tyrosine Kinase	2007	175
Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations Kenichi Sato, Taku Hatano, Kazuo Yamashiro, Movement Disorders	2006	145
Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease Shinji Saiki, Taku Hatano, Motoki Fujimaki, Scientific Reports	2017	140
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial Günter U. Höglinger, Irene Litvan, Nuno Mendonça, The Lancet Neurology Clinical TrialsProgressive Supranuclear PalsyPlacebo-controlled TrialPharmacotherapyPain Management	2021	130
Neurite orientation dispersion and density imaging in the substantia nigra in idiopathic Parkinson disease Koji Kamagata, Taku Hatano, Ayami Okuzumi, European Radiology EngineeringNeuroimaging ModalityMedical ImagingDensity ImagingSubstantia Nigra	2015	125

Page 1